Unfortunately, this study was prematurely terminated due to high toxicity (Singhal et al., 2015) and one additional trial using ER antagonist plus AI (fulvestrant and anastrozole) as consolidation therapy in postmenopausal women with advanced NSCLC (NCT00932152) was terminated due to poor recruitment. The gene discussed is ESR1; the disease is non-small cell lung carcinoma.